Tobira Therapeutics Inc. Receives Additional US Patent on Cenicriviroc
10/26/2012 7:37:09 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics, Inc., developer of innovative antiretroviral therapies for HIV, today announced the United States Patent and Trademark Office has issued patent 8,183,273, claiming compositions of matter of a broad family of compounds with activity against chemokine receptors CCR5 and CCR2. The most advanced drug candidate in this family of compounds, Tobira’s cenicriviroc, is currently in Phase 2b clinical evaluation for the treatment of HIV-1 infection. This is the second composition of matter patent issued to Tobira in the United States, expanding coverage of Tobira’s portfolio of chemokine inhibitors.